Bonus: What You Need to Know About the Novavax COVID-19 Protein-Based Vaccine
Public Health On Call
The Johns Hopkins Bloomberg School of Public Health
4.6 • 644 Ratings
🗓️ 16 June 2022
⏱️ 17 minutes
🧾️ Download transcript
Summary
An FDA advisory panel recommended Emergency Use Authorization for the two-dose Novavax COVID-19 vaccine for people ages 18+. The vaccine is built on a different technology than others currently authorized in the US, and significant delays in manufacturing and authorization have slowed down its entry into the US market. Vaccine expert Dr. Bill Moss returns to the podcast to talk with Lindsay Smith Rogers about Novavax and its potential and what's behind the delays.
Transcript
Click on a timestamp to play from that location
| 0:00.0 | Welcome to Public Health On Call, a podcast from the Johns Hopkins Bloomberg School of Public Health. |
| 0:12.0 | I'm Joshua Sharfstein, Vice Dean for Public Health Practice and Community Engagement, |
| 0:16.9 | and a former health commissioner here in Baltimore. |
| 0:19.7 | Our goal is to bring evidence and experience |
| 0:22.1 | to illuminate critical public health issues. If you have questions or ideas for us, please send |
| 0:27.7 | an email to public health question at jhhhu.edu. That's public health question at jhhu.edu for future |
| 0:35.4 | podcast episodes. |
| 0:40.8 | Hi, I'm Lindsay Smith Rogers, producer of public health on call. |
| 0:47.1 | And today I talk with vaccine expert Dr. Bill Moss about NovaVex's COVID-19 vaccine. |
| 0:51.0 | What makes this vaccine different from others available in the U.S. And why have there been delays in bringing the product to market? |
| 0:54.6 | Let's listen. |
| 0:56.1 | Bill Moss, thank you so much for joining us today. |
| 0:59.0 | An FDA advisory panel recommended emergency use authorization for the two-dose Novavax vaccine for people 18 and over. |
| 1:08.3 | So tell us about Novavax. |
| 1:10.3 | What makes this vaccine unique? |
| 1:12.6 | Yes, and thank you, Lindsay, for having me. This is a different type of vaccine than what we |
| 1:18.2 | currently have under emergency use authorization here in the United States. As our listeners will |
| 1:23.7 | know, we have two messenger RNA vaccines under emergency use authorization, and then the |
| 1:28.8 | Johnson and Johnson adenovirus-pected vaccine. All of those vaccines, they have kind of a similar |
| 1:35.9 | process where the gene for this, which is the genetic recipe for the spike protein, |
| 1:40.9 | is introduced into our own cells, and our own cells make the protein |
| 1:46.2 | to which our immune system responds. The Novavax in some ways is an older, much older technology |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from The Johns Hopkins Bloomberg School of Public Health, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of The Johns Hopkins Bloomberg School of Public Health and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.